Quarterly Result7 Aug 2025, 03:51 pm
Hikal Ltd. Reports Q1 FY26 Earnings: Revenue at Rs 380 Crore, EBITDA at Rs 25 Crore
AI Summary
Hikal Ltd., a preferred long-term partner for leading global life sciences companies, announced its unaudited financial results for the quarter ended 30th June 2025. The consolidated revenue stood at Rs. 380 Crore with an EBITDA of Rs. 25 Crore. The pharmaceutical segment delivered revenue of Rs. 203 Cr with an EBIT margin of -12.9%. The crop protection business reported revenue of Rs. 178 Cr with an EBIT margin of 9.7%. Despite challenges, the company remains confident of delivering on its guidance for FY26.
Key Highlights
- Revenue recorded at Rs 380 Crore; impacted by deferred offtake post USFDA OAl in May 2025
- EBITDA stood at Rs. 25 crore; PAT stood at Rs. (23) Crore
- Pharmaceutical segment delivered revenue of Rs. 203 Cr with an EBIT margin of -12.9%
- Crop protection business reported revenue of Rs. 178 Cr with an EBIT margin of 9.7%
- Company remains confident of delivering on its guidance for FY26